Cagrilintide
2.4 mg · Weekly
Evidence
- Human Studies
- 8
- Animal Studies
- 15
- Clinical Status
- Investigational
- Confidence
- Moderate
- Long-Term Safety
- Established short/medium-term in Phase 2/3 trials; not yet FDA approved, so no long-term post-approval surveillance data exists yet
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
Cagrilintide is a long-acting amylin receptor agonist that promotes satiety through a different pathway than GLP-1 drugs, and is being developed in combination with semaglutide (as "CagriSema") for weight management. As of this writing it has not received FDA approval on its own or in combination.
Common Protocols
- Weekly subcutaneous injection, titrated up over months in published trials — dosing outside a trial or prescription is not established
Side Effects
- GI side effects (nausea, vomiting, diarrhea, constipation) similar to GLP-1 drugs, common especially during titration
- Injection site reaction
Interactions
- May compound GI side effects when combined with GLP-1/GIP-class medications, which is also the basis of its intended combination use — clinician supervision matters
Practical Details
- Cost
- $$$
- Typical Vial Size
- 10 mg
- Storage
- Refrigerate after reconstitution
Research Links
Long-acting amylin analogue; studied combined with semaglutide as CagriSema